Celebrating our milestones 

It all started in 1983 with a single idea: people with haemophilia deserve access to better products. Today we help thousands of patients worldwide.  

Celebrating our milestones

Octapharma demonstrates commitment to improving haemophilia A treatment at EAHAD

Octapharma demonstrates commitment to improving haemophilia A treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)

Isaiah tiene ahora ocho años y lleva enfermo desde que tenía dos. Durante años le costaba ganar peso, pero sus médicos no sabían porqué. Danielle, ahora defensora del paciente, hizo todo lo que estaba en su mano para ponerlo en contacto con los especialistas y tratamientos adecuados, pero nada parecía surtir efecto.

¡Mi hijo es un guerrero!

Informe Anual 2022

40 años de Octapharma

Octapharma se fundó hace 40 años para suministrar a los pacientes con hemofilia un concentrado de factor VIII (FVIII) más seguro y de mejor calidad.

Todo empezó con una convicción

Update of Summary of Product Characteristics for Nuwiq® 

Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis

From childhood dream to research team

Andrea is Team Leader for Plasma R&D in Vienna.

Andrea and her team’s latest challenges focus on designing two new developments for our pooled plasma products.

Positive results for fibryga published in the Journal of Thrombosis and Haemostasis

The final results of the Phase 3 clinical trial investigating fibryga® for the treatment of bleeding and surgical prophylaxis in patients with congenital fibrinogen deficiency (FORMA-02) has been published in the Journal of Thrombosis and Haemostasis (JTH).  FORMA-02

Positive results for fibryga, fibrinogen deficiency, Journal of Thrombosis and Haemostasis. FORMA-02

Positive results for fibryga® in the treatment of bleeding and surgical prophylaxis in patients with congenital fibrinogen deficiency (FORMA-02) published in the Journal of Thrombosis and Haemostasis

En 2008, Elyse tuvo un terrible accidente de coche que la dejó incapacitada para caminar durante más de 18 meses. Aunque no recuerda mucho de ese día, sí le queda la imagen de lo que le salvó la vida: una transfusión de plasma.

Sin plasma, no estaría viva ahora

Always on the go

Clinical nurse educator Laurel has little time to rest when she is travelling the country to meet healthcare professionals and educate them about subcutaneous immunoglobulin therapy and primary immunodeficiency diseases.

Annual Report 2019

Octapharma Group reports strong results for 2018

ommenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products."

Octapharma Group publishes 2017 annual results

Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017.

Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million

Persistence - and ingenuity - pays off

Christoph and his team relish a challenge.

Timely help for critically ill patients

Final results from the NuProtect study demonstrating efficacy of Nuwiq

Final results from the NuProtect study demonstrating efficacy of Nuwiq® in PUPs

Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019

La transfusión prehospitalaria

Los profesionales de la salud disponen de un variado rango de opciones de tratamiento cuando el paciente sufre una pérdida significativa de sangre en el marco hospitalario, pero la situación se complica mucho fuera de él. Una de las decisiones claves es la de transfundir o no sangre y hemoderivados.

Transfundir o no: Una complicada cuestión para los cuidados críticos prehospitalarios

Why worry?

Arne was diagnosed with a primary immunodeficiency disease (#PIDD) when he was two years old. What first appeared to be pneumonia turned out to be XLA. But he doesn’t let his condition stop him from living a normal life. 

Octapharma Group publishes 2016 annual results 

The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015.

Octapharma Group publishes 2016 annual results

Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million

New Data on Haemophilia A or von Willebrand Disease at ISTH 2019

Octapharma to Present New Data on Management of People with Haemophilia A or von Willebrand Disease at ISTH 2019

Octapharma share promising preclinical data for SubQ-8

Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK.

Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018

Medicine as an art form

Ruth Wagner, Group Manager R&D Cell Line Development at Octapharma

Ruth is Group Manager R&D Cell Line Development at the Octapharma Biopharmaceuticals centre in Heidelberg.

Having the right balance of different talents in a team is a key contributing factor to innovation.

Trust, swift decision making and excellent medical skills are a priority for Intensive care

Gennadiy Galstyan, MD, PhD, heads the Department of Intensive Care at the National Research Center for Hematology in Russia.

Trust and decision making 

Low inhibitor rate with octanate® in previously untreated patients

Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia.

Low inhibitor rate with octanate®

Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Final results from the NuProtect study

Highlighting the NuProtect study at ASH 2019

Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019

El estudio clínico ATN-106

¿Qué es la deficiencia congénita de antitrombina?

Causa

ATN-106 tiene como objetivo establecer la seguridad y eficacia del concentrado de antitrombina de Octapharma para el tratamiento de la deficiencia congénita de antitrombina.

Motivados por la curiosidad

Cuando Eva empezó a sentir fatiga extrema y debilidad muscular, era ya imposible ignorar los síntomas. “El dolor era intenso. Después de un ligero movimiento, sentía como si hubiera corrido una maratón”, recuerda.

Viviendo con el misterio de la dermatomiositis

A passion for living

Nicholas shares his journey and how he teaches #haemophilia101 to fellow patients in the 2019 Annual Report.

Octapharma activities prominent at the upcoming 2017 ISTH Congress

Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held in Berlin, Germany from 8–13 July. Octapharma is delighted to be a Platinum Sponsor of the Congress.

Octapharma activities prominent at 2017 ISTH Congress

Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany

update on the development of SubQ-8 ISTH 2019

Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019

Continuing to invest in the future prosperity of Octapharma

Letter from the Chief Financial Officer, Roger Mächler - Annual Report 2019

Octapharma to build new multi-use venue

Octapharma to invest Euro 21 million to build a new multi-use venue in Springe, Germany. Octapharma has confirmed to invest Euro 21 million to build a new multi-function facility in Springe, Germany

Octapharma has confirmed to invest Euro 21 million to build a new multi-function facility in Springe, Germany.

Octapharma to invest Euro 21 million to build a new multi-use venue in Springe, Germany

Using big data to improve lives

Angelika and her team monitor all information from the donor centre to manufacturing.

The ability to collect and access vast data sets of plasma donations is the foundation of the team.

Adam Llarena, Single Donation Controller

Switched profession – from being under heavy pressure as a hotel receptionist to working in a calmer environment

"We are Octapharma" film series

 the story of Octapharmas high-purity human fibrinogen concentrate

Members of the dedicated Octapharma human fibrinogen concentrate  team.

The science of teamwork: the story of Octapharma’s high-purity human fibrinogen concentrate

The story of Octapharma’s high-purity human fibrinogen concentrate

Octapharma present new data on the benefits of Nuwiq®

Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK.

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Octapharma’s fibryga® receives European label extension to treat acquired fibrinogen deficiency (AFD) 

Fibryga® receives European label extension to treat acquired fibrinogen deficiency (AFD) 

Financial review 2024

Bilan financier 2024

El Grupo Octapharma siguió creciendo con fuerza en 2024, impulsado por el aumento de la demanda en toda la cartera, especialmente en cuidados críticos, y las mejoras operativas que siguen incrementando la eficiencia y aportando economías de escala. 

Análisis financiero 2024

Reforzar el crecimiento futuro

Romana Wesenauer, Directora de la Cadena de Suministros Clínicos

Dmitrii Matveev, VP and Head of Clinical R&D for Immunology & Critical Care

Mantenerse ágiles en un entorno impredecible

A petición de la US Food and Drug Administration (FDA, por sus siglas en inglés), el equipo de I+D de Octapharma inició el desarrollo del ensayo clínico LEX-209 en 2016.

Una cultura empresarial

Kellie Jo has dedicated many hours to conducting her own research on dermatomyositis.

La dermatomiositis es un trastorno autoinmune raro que globalmente afecta a unas 20 – 90 personas por millón2. Los trastornos autoinmunes hacen que el sistema inmune ataque las células y tejidos del propio cuerpo.

Superando el dolor: El largo camino hasta el diagnóstico de dermatomiositis

Informe Anual 2021

Debbie oyó muchas veces mientras crecía que nunca podría tener hijos y que era poco probable que viviera hasta alcanzar los 40. Hoy, con 59 años y dos hijos de su matrimonio, se le hace difícil creer lo lejos que ha llegado y cuanto ha conseguido.

Llevando los hematomas con orgullo: Viviendo con la enfermedad de von Willebrand

La puesta en marcha de la estrategia de gestión de la sangre de los pacientes (PBM, por sus siglas en inglés) ha jugado un papel fundamental en la operación que separó a unas siamesas haitianas en el Hospital Exequiel González Cortés de Santiago de Chile. 

El PBM es la clave del éxito de la separación de gemelas siamesas

Suzanne tiene la enfermedad de  von Willebrand (VWD, por sus siglas  en inglés) tipo III, la forma más grave de  este trastorno hemorrágico hereditario.  Las personas con VWD tienen bajos niveles  de proteína VWF en sangre, o la proteína  no funciona como debería.

El sueño de formar  una familia a pesar  de la VWD

El sueño de formar una familia a pesar de la VWD

Surviving the unknown

Stories such as Sebaga’s remind us of our vision, which is to provide new health solutions advancing human life.

Surviving the unknown 

Engaging with patients

Octapharma symposium at ISTH Berlin

Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany.

Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with von Willebrand disease (VWD) and haemophilia A

New data ISTH 2019 

Octapharma presents new data on the benefits of Nuwiq® in patients with haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Cong

Octapharma presents new data on the benefits of Nuwiq® in patients with haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress

Continuing the impact of our products for generations to come

Wolfgang Marguerre, Chairman and CEO, Octapharma Group

Letter from the chairman and CEO, Octapharma Group, Wolfgang Marguerre - Annual Report 2019

An eye for detail

We are Octapharma 

We are Octapharma film series 

Testing boundaries

Thomas, together with their teams, ensure viral safety at Octapharma.

Octapharma routinely performs PCR testing on all plasma pools for HIV, HAV, HBV and parvo B19 viruses, as well as for HCV.

Testing boundaries, PCR testing plays a key role in product safety.

Octapharma announces approval of new Nuwiq® product strengths

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®.

Octapharma announces approval of new Nuwiq® product strengths in Europe

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A

Octapharma announces publication of data on fibryga

Octapharma announces publication of data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

New data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

Octapharma Group delivered strong growth in both sales and operating income in 2019

Octapharma Group delivered strong in 2019

Built on strength and resilience

Construit sur la force et la résilience

Para navegar por un panorama económico y competitivo cada vez más complejo, en 2024 afinamos nuestro enfoque para mejorar aún más la resiliencia de Octapharma y preservar la vitalidad de nuestro negocio.

Construido sobre la fuerza y la resiliencia

Carta del Presidente y Director General

Octapharma USA today sponsored the patient symposium “Hope Ignites: Stories to Inspire,” during the Hemophilia Federation of America (HFA) Annual Symposium in Providence, Rhode Island.

Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’

Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’ Program at Hemophilia Federation of America Annual Symposium

Real hope for Brandon

Blood is essential for the wellbeing of everyone.

Blood is essential for the wellbeing of everyone

Rute Martins, Customer Service Manager at Corporate Customer Service

Rute and her team handle all the orders for finished products and other enquiries coming from 115 countries around the globe.

Getting our medicines to patients

Bringing new optimal therapies to patients in need

Bringing new optimal therapies

Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress, Octapharma’s active involvement includes two sponsored scientific symposia.

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® 

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data

Fibryga® receives Swissmedic approval

Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

Octapharma receives Swissmedic approval for fibryga®

Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with bleeding disorders, including Chris Bombardier.

Octapharma USA Sponsors NHF Annual Meeting

Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements

Strong commitment for the two brothers from Estonia

One in ten patients coming into hospital will require a blood transfusion.

One in ten patients coming into hospital will require a blood transfusion

One in ten patients

Centre management collaborate to ensure quality and traceability of plasma collected.

Our valued donors provide life-saving plasma for the medicines we create.

Saving lives starts with our donors

Saving lives

 Technician, operator and shift leader discussing the next packaging steps.

Semi-automatic visual inspection using a magnifying glass.

Inspecting finished products with intense concentration

Inspecting finished products

Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017.

Octapharma underlines strong commitment to haemophilia A patients

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®

Octapharma announced today the launch of the Canadian PREVAIL (Immune Tolerance Induction in Hemophilia A Patients using wilate®) study for patients with Hemophilia A.

New Canadian study to improve eradication of inhibitors in Hemophilia A patients

New Canadian study to improve eradication of inhibitors

Octapharma USA has provided a grant to support the final leg of the inspirational journey of Chris Bombardier, who hopes to become the first person with severe Hemophilia to climb the Seven Summits of the world.

Noticias

Sobre nosotros

Plasma

Productos

Carreras

Compromiso

Noticias